SVB Leerink Maintains Market Perform on Intercept Pharmaceuticals, Lowers Price Target to $17
SVB Leerink analyst Thomas Smith maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Market Perform and lowers the price target from $21 to $17.